DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES (Q2035396): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
||
| Property / financed by | |||
| Property / financed by: Directorate-General for Regional and Urban Policy / rank | |||
Revision as of 08:42, 2 November 2020
Project Q2035396 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES |
Project Q2035396 in Italy |
Statements
5,714.0 Euro
0 references
11,428.0 Euro
0 references
50.0 percent
0 references
15 November 2016
0 references
7 December 2018
0 references
3 December 2018
0 references
TAKIS SRL
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
L'AZIENDA DI BIOTECNOLOGIE TAKIS PRODUCE IN MODO INNOVATIVO ED EFFICACE ANTICORPI MONOCLONALI PER CONTO PROPRIO E PER CONTO TERZI. SEBBENE MOLTO COMPETITIVA NEI PROTOCOLLI DI VACCINAZIONE, IL PROCESSO ATTUALE MANCA DI UN SISTEMA ROBOTIZZATO PER L (Italian)
0 references
THE BIOTECH COMPANY IS INNOVATIVE AND EFFECTIVE MONOCLONAL ANTIBODIES FOR OWN ACCOUNT AND FOR HIRE OR REWARD. ALTHOUGH HIGHLY COMPETITIVE IN VACCINATION PROTOCOLS, THE CURRENT PROCESS LACKS A ROBOTIC SYSTEM FOR (English)
0 references
Identifiers
F83G17000640007
0 references